Isigulana sokuqala sithathiwe ngoNyango olutsha lwe-Hepatocellular Carcinoma

I-Kintor Pharmaceutical Limited namhlanje ibhengeze idosi yesigulana sokuqala e-United States solingo lwezonyango lwenqanaba lesibini lengingqi (NCT05178043) ye-ALK-1 antibody (GT90001) kunye ne-Nivolumab (Opdivo) yonyango oludityanisiweyo lonyango lwe-Hepatocellular Carcinoma (HCC) nge-2 kaMeyi 2022.

NgokweGlobal Cancer Statistics 2020, umhlaza wesibindi ungowesithandathu ufunyaniswa ukuba ngumhlaza kwaye ungowesithathu unobangela wokufa komhlaza kwihlabathi liphela, malunga ne-906,000 yeemeko ezintsha kunye ne-830,000 yokusweleka[1]. I-HCC yeyona ndlela ixhaphakileyo yomhlaza wesibindi kubantu abadala, ibalelwa malunga ne-75% -85% yazo zonke ii-cancer zesibindi. Lilonke, unyango kunye noxilongo lomhlaza wesibindi luhlwempuzekile, kwaye ukusinda kukonke komhlaza wesibindi kufuneka kuphuculwe ngakumbi ngeendlela ezingcono zonyango.

Kwiminyaka yakutshanje, iindlela ezintsha zonyango ziye zandisa iindlela zokukhetha izigulana ezinomhlaza wesibindi. Ngo-2020, unyango oludityanisiweyo lwe-Atezolizumab (TECENTRIQ®) kunye ne-Bevacizumab (AVASTIN®) (“T+A”) yamkelwa e-US ukuba ithathe indawo ye-Sorafenib (NEXAVAR®) okanye i-Lenvatinib (LENVIMA®) njengomgangatho womgca wokuqala inkathalo (“SOC”) ye-HCC ephucukileyo, ilandela ngokuvunywa kwamanye amazwe amaninzi nakwimimandla. Kubekho iimfuno ezinkulu ezingafezekiswanga zonyango lodidi lwesibini kwizigulane ezingaluphumelelanga unyango okanye ezingayinyamezeliyo i-T+A.

UGqr. Tong Youzhi, umseki, uSihlalo, kunye ne-CEO ye-Kintor Pharma, uthe, "Siyavuya ukugqiba umthamo wokuqala wesigulana kwisigaba se-II solingo lwezonyango lwengingqi ye-GT90001 ludityaniswe ne-Nivolumab kunyango lwe-HCC ephezulu. Silindele ukuba esi sigaba sesi-II sophononongo lwe-MRCT lubeke i-GT90001 kunye nomgqatswa odibeneyo kunye ne-I/O kunyango lodidi lwesibini lwe-HCC. Sikwakhetha iindlela zonyango ze-GT90001 kwamanye amathumba aqinileyo kwaye sinethemba lokuzisa iindlela ezintsha zonyango kwizigulana ezinezidingo ezingafezekanga.